Vitamin C Side Effects

Reported Vitamin C side effects

Vitamin C has an excellent safety profile at typical supplementation doses (200-1,000 mg daily). Serious adverse effects are rare and are largely limited to specific clinical scenarios. The vitamin's water solubility, regulated absorption, and renal excretion contribute to a wide therapeutic margin. Common side effects at high oral doses: Gastrointestinal upset: nausea, heartburn, abdominal cramping, osmotic diarrhea. These emerge typically above 2,000 mg daily, especially when taken as ascorbic acid (vs. mineral ascorbate buffered forms). Dose-dependent; resolves with dose reduction or switching to buffered form or esterified form. Flushing: rare; possibly due to histamine release. Dental erosion (from chewable ascorbic acid tablets): the acidic pH can erode enamel with chronic use. Avoid chewable acidic forms for daily use; if chewables are used, rinse mouth with water afterward. Kidney stone risk. Vitamin C is metabolized in part to oxalate, which combines with calcium in the urinary tract to form calcium oxalate stones. High-dose chronic vitamin C supplementation (>1,000 mg/day) modestly increases urinary oxalate excretion and may increase kidney stone risk, particularly in men and in individuals with prior history of calcium oxalate stones or other risk factors. Thomas et al. (PMID 23381591) found a 43% increased risk of kidney stones in men taking ≥1,000 mg/day versus non-users in the Cohort of Swedish Men. Women appear less susceptible in most studies. Practical guidance: individuals with a history of calcium oxalate kidney stones should limit vitamin C to ≤500 mg daily, hydrate well, and discuss with their nephrologist or urologist. Buffered ascorbate forms (calcium, magnesium, sodium ascorbate) are not clearly advantaged over ascorbic acid for stone risk; total oxalate production is similar. Iron overload potentiation. Vitamin C enhances non-heme iron absorption and also reduces Fe³⁺ to Fe²⁺. In patients with hereditary hemochromatosis (HFE mutations), thalassemia major, or transfusion-dependent anemia, high-dose vitamin C supplementation can worsen iron overload and contribute to organ damage. Such patients should not take vitamin C supplements above RDA doses and should discuss with their hematologist. Vitamin C from food is not restricted unless supplementation levels are being exceeded. G6PD deficiency hemolysis (at very high doses). Glucose-6-phosphate dehydrogenase deficiency is the most common enzyme deficiency worldwide, particularly among individuals of African, Mediterranean, and Asian descent. At very high doses—typically IV vitamin C at gram levels, rarely at oral gram doses—vitamin C can precipitate hemolysis in G6PD-deficient individuals via oxidative stress overwhelming residual antioxidant capacity. This is a specific concern for IV vitamin C protocols, which should test G6PD status before initiating. Oral doses ≤2 g daily are generally considered safe even in G6PD deficiency, but dose-dependent risk exists. Interference with laboratory tests. High-dose vitamin C can cause false-negative urine glucose dipstick results and false-positive blood glucose readings on some point-of-care meters (glucose oxidase-based). It can also interfere with stool occult blood testing, producing false-negative results and masking GI bleeding. Patients undergoing relevant testing should disclose vitamin C supplementation and hold doses for 24-48 hours before testing if feasible. Exercise adaptation blunting. Chronic high-dose vitamin C supplementation (≥1 g daily) during training periods may reduce exercise-induced mitochondrial biogenesis and other adaptive responses by scavenging the reactive oxygen species that drive these adaptations (Ristow et al.; Paulsen et al.). Athletes pursuing peak adaptation should avoid chronic gram-level vitamin C dosing during key training blocks. Standard dietary intake or modest 200-500 mg/day does not appear to interfere meaningfully. Interactions with cancer chemotherapy. Theoretical concerns exist about vitamin C (particularly IV) interacting with chemotherapy—either enhancing or interfering with cytotoxic effects depending on the agent and context. Patients undergoing active chemotherapy should discuss vitamin C supplementation with their oncology team before initiating or continuing; the field has moved from general prohibition to nuanced context-dependent recommendations, but individual coordination is essential. Copper overload/Wilson disease: Not a direct contraindication, but theoretical interaction with copper metabolism. Most Wilson disease patients do not need to restrict vitamin C specifically beyond their overall dietary copper management plan. Allergic reactions. True allergy to ascorbic acid is very rare. More common: reaction to tablet excipients or capsule fillers. Switching to a cleaner product or pure ascorbic acid powder usually resolves. Population-specific considerations: Pregnancy and lactation: Vitamin C at RDA doses (85 mg/day pregnant, 120 mg/day lactating) is safe. Supplementation up to 200-500 mg daily is generally considered safe. Very high doses (>2,000 mg/day) during late pregnancy have been associated with rebound scurvy in the newborn (the infant adapted to high maternal levels then drops to typical intake after birth), though this is rare. Stay within moderate supplementation ranges during pregnancy. Children: Pediatric RDAs are age-scaled (15-45 mg/day for ages 1-13). Childhood scurvy still occurs, especially in children with severe food selectivity, autism spectrum disorder, or malnutrition; awareness of this is important. Routine high-dose supplementation is not recommended for most children; dose is adjusted to age and indication. Elderly: Higher baseline rates of subclinical deficiency due to reduced fruit/vegetable intake, polypharmacy, and reduced absorption efficiency. Supplementation at 100-500 mg daily is reasonable for many older adults. Smokers: Tobacco smoke depletes vitamin C via oxidative stress; RDA includes an additional 35 mg/day for smokers. Supplementation at 200-500 mg daily is reasonable. Diabetics: Vitamin C modestly improves endothelial function and glycemic markers in diabetic populations. Supplementation at standard doses is generally beneficial. Be aware of glucose test interference at gram-level doses. Renal insufficiency: In chronic kidney disease, decreased renal clearance may raise plasma oxalate; limit supplementation to ≤500 mg/day and coordinate with nephrology. Thalassemia/hemochromatosis: Limit to RDA doses; do not take high-dose vitamin C. Tolerable Upper Intake Level (UL): The U.S. Institute of Medicine sets the UL at 2,000 mg/day for adults, based on the risk of osmotic diarrhea and gastrointestinal discomfort. This is a GI-tolerability threshold, not a toxicity threshold; short-term excursions are generally safe, but chronic exceedance increases kidney stone risk in susceptible populations. Overdose: Accidental ingestion of gram-quantities of vitamin C has not produced serious toxicity in case reports. Management is supportive. Extreme acute doses produce severe osmotic diarrhea and possibly vomiting; these are self-limiting and resolve with fluid replacement. In summary, vitamin C is very safe at conventional supplementation doses. The main dose-dependent concerns are GI intolerance above 2 g/day, modest kidney stone risk at chronic gram-plus doses especially in men with stone history, iron overload potentiation in hemochromatosis/thalassemia, and potential exercise adaptation interference in athletes at chronic high doses. For most healthy adults, 200-1,000 mg daily is well within the safety margin and poses minimal risk.

When to continue, reduce, or stop Vitamin C

Vitamin C contraindications

Absolute contraindications: Hereditary hemochromatosis with iron overload: vitamin C enhances iron absorption and reduces Fe³⁺ to Fe²⁺, worsening iron overload and potentially contributing to organ damage (heart, liver, pancreas). These patients should limit vitamin C to RDA levels (90 mg) from food or modest supplements and avoid high-dose supplementation. Thalassemia major and other iron-overload states requiring chronic transfusion: same concern as hemochromatosis. Discuss any supplementation with hematology. Severe oxalate kidney stone history with ongoing stone risk: high-dose chronic vitamin C (>1 g/day) can increase oxalate stone risk. Limit to ≤500 mg daily and hydrate well. Severe G6PD deficiency receiving IV vitamin C: risk of oxidative hemolysis at pharmacologic IV doses. Oral supplementation at typical doses is safer but should still be discussed with hematology. Relative contraindications / caution: Active chemotherapy or radiation therapy: context-dependent interaction with treatment efficacy and toxicity. Coordinate with oncology team before starting or continuing vitamin C supplementation. Chronic kidney disease (eGFR <60 mL/min/1.73m²): limit to ≤500 mg/day supplemental; risk of hyperoxaluria with higher doses. Dialysis patients: vitamin C is not well-cleared by dialysis; some centers recommend specific supplementation, others restrict. Follow nephrology team guidance. Calcium oxalate kidney stone history (any severity): limit to ≤500 mg daily; emphasize dietary sources; hydrate to maintain dilute urine. Active gastric ulcer or severe GERD: acidic ascorbic acid may aggravate; use buffered form (sodium/calcium/magnesium ascorbate). Chronic high-dose NSAID use with GI concerns: similar caution; buffered form preferred. Smoker pursuing maximum training adaptation: chronic gram-level vitamin C may blunt exercise adaptation (Ristow/Paulsen). Consider lower doses during key training blocks. Hyperoxaluria (primary or secondary): avoid high-dose vitamin C. Drug interactions: Warfarin: can modestly reduce INR at high doses; monitor if initiating high-dose vitamin C in a warfarin patient. Coordinate with anticoagulation clinic. Aluminum-containing antacids: vitamin C can increase aluminum absorption; minor concern with chronic co-use. Cyclosporine: vitamin C may reduce cyclosporine levels theoretically; monitor if using both. Estrogen/oral contraceptives: vitamin C may modestly increase estrogen levels in some studies; clinical significance minor. Iron supplements: enhancement of absorption; clinically beneficial in iron deficiency, harmful in iron overload. Chemotherapy agents: context-dependent; coordinate with oncology. Chelation therapy (EDTA, desferrioxamine): interactions possible; coordinate with clinician. Aspirin: chronic aspirin reduces plasma vitamin C modestly; ensure adequate intake. Acetaminophen/paracetamol: vitamin C may reduce acetaminophen clearance; clinical significance minor. Populations requiring clinician input before high-dose supplementation: Active cancer patients Hemochromatosis and iron overload disorders Severe kidney disease History of recurrent calcium oxalate kidney stones Warfarin users Patients on chemotherapy or complex medication regimens Thalassemia patients Pediatric specific: Oral pediatric supplementation at age-appropriate RDA doses (15-75 mg/day) is safe and sometimes beneficial for children with restrictive diets. Infant formula and breast milk provide adequate vitamin C; supplementation not routinely needed in healthy infants. Scurvy in children with severe food selectivity, autism spectrum disorder, or malnutrition—consider in differential diagnosis of unexplained bleeding, irritability, or failure to thrive. High-dose supplementation (>1 g/day) in children is rarely indicated; discuss with pediatrician if considering. Pregnancy and lactation: RDA: 85 mg/day pregnant, 120 mg/day lactating. Supplementation up to 200-500 mg daily is generally considered safe. Very high doses (>2 g/day) in late pregnancy may theoretically predispose newborn to rebound scurvy; rare but has been reported. Moderate intakes avoid this concern. Standard prenatal vitamins contain 85-120 mg; additional modest supplementation is fine; avoid gram-level supplementation in pregnancy without obstetric guidance. Vitamin C has been investigated for preeclampsia and preterm birth prevention with largely disappointing results in RCTs; not routinely recommended at high doses for these indications. Elderly specific: Reduced dietary intake and absorption efficiency common in older adults. Supplementation at 500-1,000 mg daily generally beneficial and safe in absence of renal or iron-overload contraindications. Polypharmacy screening for drug interactions recommended. Overdose: Acute oral overdose: severe osmotic diarrhea, abdominal cramping, nausea; self-limiting and resolves with fluid replacement. No serious acute oral toxicity reported in case literature. IV overdose (rare, typically from clinical dosing error): hemolysis in G6PD deficient, possible renal oxalate deposition. Management: supportive; hydration; monitor renal function. Pre-operative considerations: Routine 500-1,000 mg daily vitamin C does not require discontinuation before most surgeries; may support wound healing. Very high doses should be reduced to routine levels 1-2 weeks pre-op if high-dose oncology protocols are being used. Disclose all supplementation to surgical team. Special considerations for IV vitamin C: Mandatory G6PD screening before IV Renal function assessment Iron overload screening Blood pressure monitoring during infusion Coordination with primary medical team Not available for self-administration In practical terms, oral vitamin C at conventional doses (up to 1,000 mg/day) is very safe for the overwhelming majority of adults. The meaningful contraindications are iron overload disorders, severe kidney stone history, and specific chemotherapy contexts. The main safety issue for most users is simply GI tolerance of higher doses, easily managed by dose adjustment or form selection.

Why vendor quality drives Vitamin C side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Vitamin C side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .